Literature DB >> 23907125

Genetic variants and mutations of PPM1D control the response to DNA damage.

Crissy Dudgeon1, Sathyavageeswaran Shreeram, Kan Tanoue, Sharlyn J Mazur, Ahmed Sayadi, Robert C Robinson, Ettore Appella, Dmitry V Bulavin.   

Abstract

The Wip1 phosphatase is an oncogene that is overexpressed in a variety of primary human cancers. We were interested in identifying genetic variants that could change Wip1 activity. We identified 3 missense SNPs of the human Wip1 phosphatase, L120F, P322Q, and I496V confer a dominant-negative phenotype. On the other hand, in primary human cancers, PPM1D mutations commonly result in a gain-of-function phenotype, leading us to identify a hot-spot truncating mutation at position 525. Surprisingly, we also found a significant number of loss-of-function mutations of PPM1D in primary human cancers, both in the phosphatase domain and in the C terminus. Thus, PPM1D has evolved to generate genetic variants with lower activity, potentially providing a better fitness for the organism through suppression of multiple diseases. In cancer, however, the situation is more complex, and the presence of both activating and inhibiting mutations requires further investigation to understand their contribution to tumorigenesis.

Entities:  

Keywords:  ATM; Chk2; PPM1D; Wip1; genetic variants; human cancer; mutations

Mesh:

Substances:

Year:  2013        PMID: 23907125      PMCID: PMC3865055          DOI: 10.4161/cc.25694

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  27 in total

1.  Wip1 phosphatase modulates ATM-dependent signaling pathways.

Authors:  Sathyavageeswaran Shreeram; Oleg N Demidov; Weng Kee Hee; Hiroshi Yamaguchi; Nobuyuki Onishi; Calvina Kek; Oleg N Timofeev; Crissy Dudgeon; Albert J Fornace; Carl W Anderson; Yasuhiro Minami; Ettore Appella; Dmitry V Bulavin
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

2.  Intrinsic kinase activity and SQ/TQ domain of Chk2 kinase as well as N-terminal domain of Wip1 phosphatase are required for regulation of Chk2 by Wip1.

Authors:  Akinori Yoda; Xiao Zhou Xu; Nobuyuki Onishi; Kyoko Toyoshima; Hiroko Fujimoto; Naoko Kato; Isao Oishi; Takeshi Kondo; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

3.  Substrate specificity of the human protein phosphatase 2Cdelta, Wip1.

Authors:  Hiroshi Yamaguchi; Giuseppina Minopoli; Oleg N Demidov; Deb K Chatterjee; Carl W Anderson; Stewart R Durell; Ettore Appella
Journal:  Biochemistry       Date:  2005-04-12       Impact factor: 3.162

4.  Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase.

Authors:  H Fujimoto; N Onishi; N Kato; M Takekawa; X Z Xu; A Kosugi; T Kondo; M Imamura; I Oishi; A Yoda; Y Minami
Journal:  Cell Death Differ       Date:  2005-11-25       Impact factor: 15.828

5.  PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.

Authors:  Xiongbin Lu; Bonnie Nannenga; Lawrence A Donehower
Journal:  Genes Dev       Date:  2005-05-03       Impact factor: 11.361

6.  Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome.

Authors:  Panayiotis Loukopoulos; Tatsuhiro Shibata; Hiroto Katoh; Akiko Kokubu; Michiie Sakamoto; Ken Yamazaki; Tomoo Kosuge; Yae Kanai; Fumie Hosoda; Issei Imoto; Misao Ohki; Jyoji Inazawa; Setsuo Hirohashi
Journal:  Cancer Sci       Date:  2007-01-12       Impact factor: 6.716

7.  Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.

Authors:  Bonnie Nannenga; Xiongbin Lu; Melissa Dumble; Marc Van Maanen; Thuy-Ai Nguyen; Richard Sutton; T Rajendra Kumar; Lawrence A Donehower
Journal:  Mol Carcinog       Date:  2006-08       Impact factor: 4.784

8.  Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway.

Authors:  Dmitry V Bulavin; Crissy Phillips; Bonnie Nannenga; Oleg Timofeev; Larry A Donehower; Carl W Anderson; Ettore Appella; Albert J Fornace
Journal:  Nat Genet       Date:  2004-02-29       Impact factor: 38.330

9.  Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase.

Authors:  Sathyavageeswaran Shreeram; Weng Kee Hee; Oleg N Demidov; Calvina Kek; Hiroshi Yamaguchi; Albert J Fornace; Carl W Anderson; Ettore Appella; Dmitry V Bulavin
Journal:  J Exp Med       Date:  2006-12-11       Impact factor: 14.307

10.  Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.

Authors:  Petra Kleiblova; Indra A Shaltiel; Jan Benada; Jan Ševčík; Soňa Pecháčková; Petr Pohlreich; Emile E Voest; Pavel Dundr; Jiri Bartek; Zdenek Kleibl; René H Medema; Libor Macurek
Journal:  J Cell Biol       Date:  2013-05-06       Impact factor: 10.539

View more
  22 in total

1.  Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma.

Authors:  Mwangala Precious Akamandisa; Kai Nie; Rita Nahta; Dolores Hambardzumyan; Robert Craig Castellino
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

Review 2.  Wip1 phosphatase in breast cancer.

Authors:  A Emelyanov; D V Bulavin
Journal:  Oncogene       Date:  2014-11-10       Impact factor: 9.867

Review 3.  Somatic Mutations in Cardiovascular Disease.

Authors:  J Brett Heimlich; Alexander G Bick
Journal:  Circ Res       Date:  2022-01-07       Impact factor: 17.367

Review 4.  Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis.

Authors:  Juan Bautista Menendez-Gonzalez; Neil P Rodrigues
Journal:  Methods Mol Biol       Date:  2022

5.  PPM1D in Solid and Hematologic Malignancies: Friend and Foe?

Authors:  Linda Zhang; Joanne I Hsu; Margaret A Goodell
Journal:  Mol Cancer Res       Date:  2022-09-02       Impact factor: 6.333

6.  DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes.

Authors:  Giorgio Em Melloni; Alessandro Ge Ogier; Stefano de Pretis; Luca Mazzarella; Mattia Pelizzola; Pier Giuseppe Pelicci; Laura Riva
Journal:  Genome Med       Date:  2014-06-10       Impact factor: 11.117

7.  Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma.

Authors:  Sulai Liu; Lin Qi; Weiqing Han; Weqing Han; Xinxing Wan; Shusuan Jiang; Yuan Li; Yu Xie; Longfei Liu; Fuhua Zeng; Zhizhong Liu; Xiongbing Zu
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

8.  Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.

Authors:  Liwei Zhang; Lee H Chen; Hong Wan; Rui Yang; Zhaohui Wang; Jie Feng; Shaohua Yang; Siân Jones; Sizhen Wang; Weixin Zhou; Huishan Zhu; Patrick J Killela; Junting Zhang; Zhen Wu; Guilin Li; Shuyu Hao; Yu Wang; Joseph B Webb; Henry S Friedman; Allan H Friedman; Roger E McLendon; Yiping He; Zachary J Reitman; Darell D Bigner; Hai Yan
Journal:  Nat Genet       Date:  2014-06-01       Impact factor: 38.330

9.  Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.

Authors:  Sona Pechackova; Kamila Burdova; Jan Benada; Petra Kleiblova; Gabriela Jenikova; Libor Macurek
Journal:  Oncotarget       Date:  2016-03-22

Review 10.  Wip1 phosphatase: between p53 and MAPK kinases pathways.

Authors:  Anastasia R Goloudina; Elena Y Kochetkova; Tatyana V Pospelova; Oleg N Demidov
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.